Synairgen plc – Raises up to £87 million
Synairgen is an AIM listed leading respiratory disease drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic has raised up to £87 million to begin the Phase III trial for a potential inhaled treatment for COVID-19.
The fundraising was structured by way of a Placing of 14,943,300 Firm Placing Shares and 30,770,985 Conditional Placing Shares, an Open Offer of up to 4,038,741 Open Offer Shares each at a price of 175 pence per Ordinary Share.
The fundraising created gross proceeds of £80 million for the Company, together with an open offer of up to c. £7 million to its existing shareholders.
The Perivan shareholder and investor communications team were delighted to work closely with the Company’s advisers including European law firm Fieldfisher and Numis Securities Limited and finnCap Ltd who acted as joint bookrunners on the Placing and on the Open Offer documentation which resulted in a significantly oversubscribed fundraising in October 2020.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed ended funds.